Clinical Trials Logo

Clinical Trial Summary

SLE disease in Saudi Arabia is yet not well defined especially in a population with high consanguinity and high inbreeding coefficient . Up until now, there has been no prospective cohort study for SLE patients in Saudi Arabia. As a result, current published literature is focused on retrospective chart reviews which are subjected to many forms of bias. so the investigator proposed this prospective registry which will follow open cohort study design aiming to provide better understanding of disease presentation, course and outcomes especially if complemented by detailed immunological, molecular, genetic and microbiome data.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04604990
Study type Observational
Source King Saud University
Contact Ibrahim Almaghlouth, MSc(c), AmBIM, FRCPC, FACR
Phone 966544282266
Email ialmaghlouth@ksu.edu.sa
Status Recruiting
Phase
Start date December 20, 2020
Completion date November 1, 2050

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06063668 - Autotaxin as Abiomarker in Systemic Lupus Erythematosus Patients
Completed NCT05624437 - BElimumab corticoSteroids Sparing Treatment in Systemic Lupus Erythematosus
Recruiting NCT06445127 - Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging) N/A
Recruiting NCT04866615 - Posterior Segment Evaluation of Patients With SLE Using OCT and OCTA
Not yet recruiting NCT04645225 - Clinical Characteristic and MEFV Gene Mutations in Patient With Juvenile Onest Systemic Lupus Erythematosus
Recruiting NCT06150651 - Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus. Phase 1
Recruiting NCT06056921 - Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease Phase 1
Recruiting NCT06294236 - Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) Phase 1
Recruiting NCT05866861 - A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus Phase 1